IDH1 and acute myeloid leukemia: However, PDX models have supported the approval of drugs for other cancers, including AG-221 and SH1573 for IDH2 R140Q-mutant acute myeloid leukemia (AML) and elacestrant for ER+ breast cancer.75, 76, 77, 78 Mutations in IDH1 and IDH2 genes are common in several cancers, including AML, where they disrupt blood cell differentiation and promote leukemogenesis.79